345832
Galectin-3C, Human, Recombinant, E. coli
ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
この商品について
NACRES:
NA.77
UNSPSC Code:
12352202
Form:
lyophilized
Assay:
≥95% (SDS-PAGE)
assay
≥95% (SDS-PAGE)
Quality Segment
form
lyophilized
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze, avoid repeated freeze/thaw cycles
impurities
≤1 EU/μg protein Endotoxin
solubility
sterile PBS: 1 mg/mL
shipped in
wet ice
storage temp.
−20°C
General description
Recombinant, human galectin-3 expressed in E. coli and subsequently cleaved with Clostridium histolyticum collagenase type VII to yield galectin-3C. The resulting galectin-3C is purified by affinity chromatography. Galectin-3C is a truncated form of galectin-3 that contains the carbohydrate binding domain but lacks the 107 amino acids at the N-terminus of galectin-3. It is suggested to play a key role in autoimmune diseases, allergic reactions, inflammation, tumor cell metastasis, atherosclerosis, and diabetes.
Physical form
Lyophilized from deionized water, 2µg lactose/µg lectin.
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). Stock solutions (in the presence of a molar excess of lactose) are stable for up to 4 months at -20°C. For use in carbohydrate binding assays the solution should be dialyzed to remove the lactose stabilizer.
Other Notes
Hoyer K.K., et al. 2004. Am. J. Pathol.164, 893.
John C.M., et al. 2003. Clin. Cancer Res.9, 2374.
Iurisci, I., et al. 2000. Clin Cancer Res6, 1389.
Van Den Brule, F. A., et al. 2000. Int. J. Cancer89, 361.
Inohara, H. 1999. Cancer85, 2475.
Nakamura, M., et al. 1999. Int. J. Oncol.15, 143.
Idikio, H., et al. 1998. Int. J. Oncol.12, 1287.
Ochieng, J., et al. 1998. Biochim. Biophys. Acta.1379 97.
Castronovo, V., et al. 1996. J. Pathol.179, 43.
Liu, F.T., et al. 1996. Biochemistry35 6073.
Schoeppner, H. L., et al. 1995. Cancer75, 2818.
Massa, S.M., et al. 1993. Biochemistry32, 260.
Oda, Y., et al. 1991. Gene99, 279.
John C.M., et al. 2003. Clin. Cancer Res.9, 2374.
Iurisci, I., et al. 2000. Clin Cancer Res6, 1389.
Van Den Brule, F. A., et al. 2000. Int. J. Cancer89, 361.
Inohara, H. 1999. Cancer85, 2475.
Nakamura, M., et al. 1999. Int. J. Oncol.15, 143.
Idikio, H., et al. 1998. Int. J. Oncol.12, 1287.
Ochieng, J., et al. 1998. Biochim. Biophys. Acta.1379 97.
Castronovo, V., et al. 1996. J. Pathol.179, 43.
Liu, F.T., et al. 1996. Biochemistry35 6073.
Schoeppner, H. L., et al. 1995. Cancer75, 2818.
Massa, S.M., et al. 1993. Biochemistry32, 260.
Oda, Y., et al. 1991. Gene99, 279.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Standard Handling (A)
保管分類
11 - Combustible Solids
wgk
WGK 2
flash_point_f
Not applicable
flash_point_c
Not applicable
適用法令
試験研究用途を考慮した関連法令を主に挙げております。化学物質以外については、一部の情報のみ提供しています。 製品を安全かつ合法的に使用することは、使用者の義務です。最新情報により修正される場合があります。WEBの反映には時間を要することがあるため、適宜SDSをご参照ください。
345832-100UG: + 345832-4MG: + 345832-UG: + 345832-0UG:
jan